NCT06230432

Brief Summary

The goal of this observational study is to learn about the biomarkers and mechanisms of severe acute pancreatitis in 30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis, and 86 patients of severe acute pancreatitis. The main question it aims to answer are: • The relationship between changes in gut microbiota and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), and the screening and validation of biomarkers that can be used for early prediction of disease severity. • Analyze the relationship between changes in blood composition and clinical prognosis (plasma inflammatory cytokines, incidence and duration of infection in various parts, mortality rate), screen and verify biomarkers that can be used for early prediction of disease severity. Blood and fecal samples from the healthy control group and diagnosed patients will be collected.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
176

participants targeted

Target at P50-P75 for all trials

Timeline
7mo left

Started Jan 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress81%
Jan 2024Dec 2026

First Submitted

Initial submission to the registry

December 29, 2023

Completed
23 days until next milestone

Study Start

First participant enrolled

January 21, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 30, 2024

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 9, 2025

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 9, 2026

Expected
Last Updated

January 30, 2024

Status Verified

January 1, 2024

Enrollment Period

1.1 years

First QC Date

December 29, 2023

Last Update Submit

January 20, 2024

Conditions

Outcome Measures

Primary Outcomes (4)

  • Composition of gut microbiota

    The gut microbiota plays an important role in protecting the intestinal barrier, regulating metabolism, and participating in immune responses in the human body, and is an important component of the gut ecosystem.

    through study completion, an average of 1 year

  • Composition of gut metabolites

    Metabolites can reveal the intrinsic correlation between metabolic products and physiological and pathological changes in the body, thereby achieving recognition of the overall state of the body.

    through study completion, an average of 1 year

  • Composition of metabolites in plasma

    Metabolites can reveal the intrinsic correlation between metabolic products and physiological and pathological changes in the body, thereby achieving recognition of the overall state of the body.

    through study completion, an average of 1 year

  • composition of proteins in plasma

    Proteins are an important material foundation for life activities and the main executors of life processes such as cell proliferation, differentiation, aging, and death.

    through study completion, an average of 1 year

Study Arms (4)

healthy control

mild acute pancreatitis

moderately severe acute pancreatitis

severe acute pancreatitis

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

30 healthy controls, 30 patients of mild acute pancreatitis, 30 patients of moderately severe acute pancreatitis and 86 patients of severe acute pancreatitis, a total of 176 cases were included.

You may qualify if:

  • Patients group:
  • ① Age between 18 and 75 years old;
  • ② Within 72 hours of AP onset;
  • ③ AP patients who meet the 2012 Atlanta AP Classification and Diagnostic Criteria.
  • Healthy control group:
  • Age between 18 and 75 years old; ② No history of acute pancreatitis; ③ Routine laboratory tests such as blood routine and fecal routine are normal.

You may not qualify if:

  • Used antibiotics, probiotics, and acid suppressants 4 weeks before enrollment;
  • Pregnant and lactating women;
  • Hypothyroidism, nephrotic syndrome, Cushing's syndrome, AIDS;
  • Chronic pancreatitis, pancreatic cancer; ⑤ Severe history of cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; ⑥ Unsigned informed consent form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

Location

MeSH Terms

Conditions

Pancreatitis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

December 29, 2023

First Posted

January 30, 2024

Study Start

January 21, 2024

Primary Completion

March 9, 2025

Study Completion (Estimated)

December 9, 2026

Last Updated

January 30, 2024

Record last verified: 2024-01

Locations